NorthWest Biotherapeutics Inc (NWBO)

[Chiugray]

Gary, On your point that DCVax-Direct will need adjuvants like Poly-ICLC to cure cancer, I agree to a point, especially for late, stage 4 aggressive cancers where immune suppression is severe.

But could the paradigm shift for a cancer cure come from an early intervention of DCVax, not just the addition of adjuvants? Because DCVax is inherently a vaccine, giving it to a cancer patient earlier, ideally at an earlier stage, provides a higher probability for a durable immune response, ie cure.

What if the reason many cancers progress to stage 4 is because:
- A patient’s initial treatment has limitations
- They do not eliminate all the cancer cells, leaving the residual cells to evolve and grow
- This gives the cancer time to develop resistance and metastasize, turning a local cancer into a later-stage, systemic, and aggressive cancer

The earlier intervention, disruptive potential of DCVax-Direct:
- Earlier diagnosis via liquid biopsies and blood tests
- Direct turnaround time is approx 3 weeks*
- First-line treatment potential
- Early treatment means clinical advantage, before the tumor can put up defenses or mutate too much
- Immune durability and low cost translate to high QALY and health insurers providing improved coverage, which is crucial for market adoption


* DCVax-Direct (no surgery, no lysate): approx 3 weeks
- Diagnosis – day 0
- Leukapheresis – 1 day
- Transport – ~2 days
- DC manufacturing - ~7 days
- Quality control, release testing – ~1 day
- Scheduling first injection – 1 week